PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2011; 6(4): e19110.
Published online Apr 19, 2011. doi:  10.1371/journal.pone.0019110
PMCID: PMC3079747
A Cyclic Undecamer Peptide Mimics a Turn in Folded Alzheimer Amyloid β and Elicits Antibodies against Oligomeric and Fibrillar Amyloid and Plaques
Peter Hoogerhout,1* Willem Kamphuis,2 Humphrey F. Brugghe,1 Jacqueline A. Sluijs,2 Hans A. M. Timmermans,1 Janny Westdijk,1 Gijsbert Zomer,1 Claire J. P. Boog,1 Elly M. Hol,2 and Germie P. J. M. van den Dobbelsteen1
1Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
2Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands
Narcis Fernandez-Fuentes, Editor
Leeds Institute of Molecular Medicine, United Kingdom
* E-mail: Peter.Hoogerhout/at/rivm.nl
Conceived and designed the experiments: PH WK JW GZ EMH GPJMvdD. Performed the experiments: PH WK HFB JAS HAMT JW GZ. Analyzed the data: PH WK JW GZ CJPB EMH GPJMvdD. Contributed reagents/materials/analysis tools: PH WK HFB JAS HAMT JW GZ. Wrote the paper: PH WK EMH.
Received December 20, 2010; Accepted March 17, 2011.
The 39- to 42-residue amyloid β (Aβ) peptide is deposited in extracellular fibrillar plaques in the brain of patients suffering from Alzheimer's Disease (AD). Vaccination with these peptides seems to be a promising approach to reduce the plaque load but results in a dominant antibody response directed against the N-terminus. Antibodies against the N-terminus will capture Aβ immediately after normal physiological processing of the amyloid precursor protein and therefore will also reduce the levels of non-misfolded Aβ, which might have a physiologically relevant function. Therefore, we have targeted an immune response on a conformational neo-epitope in misfolded amyloid that is formed in advance of Aβ-aggregation. A tetanus toxoid-conjugate of the 11-meric cyclic peptide Aβ(22–28)-YNGK′ elicited specific antibodies in Balb/c mice. These antibodies bound strongly to the homologous cyclic peptide-bovine serum albumin conjugate, but not to the homologous linear peptide-conjugate, as detected in vitro by enzyme-linked immunosorbent assay. The antibodies also bound—although more weakly—to Aβ(1–42) oligomers as well as fibrils in this assay. Finally, the antibodies recognized Aβ deposits in AD mouse and human brain tissue as established by immunohistological staining. We propose that the cyclic peptide conjugate might provide a lead towards a vaccine that could be administered before the onset of AD symptoms. Further investigation of this hypothesis requires immunization of transgenic AD model mice.
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia in elderly [1], [2]. A characteristic of the disease is formation of plaques in the brain or in brain blood vessels. These plaques originate from a membrane-bound protein, amyloid precursor protein (APP). An α-helical fragment of 39–42 amino acid residues is cleaved by β- and γ-secretases from APP thus forming a soluble amyloid β (Aβ) peptide. Soluble Aβ initially adopts an extended conformation but at high concentrations, soluble Aβ will undergo conformational changes and form oligomers, protofibrils, and fibrils. In AD, fibrillar Aβ is deposited in the brain as amyloid plaques, which is one of the main neuropathological hallmarks of the disease. However, accumulating studies suggest that the soluble oligomeric Aβ instead of insoluble Aβ in amyloid plaques is the culprit in AD [3][8] and therapeutic approaches aimed at preventing the formation of these oligomeric isoforms may be able to reduce the progression of the disease. In line with this concept, immunization of transgenic mice [9] with a suspension of “pre-aggregated” Aβ(1–42) and the adjuvant quillaja saponin 21 appeared to be beneficial. Based on these results, a phase I clinical trial was started. Antibodies present in human sera recognized plaques and Aβ deposits in brain blood vessels [10]. The antibodies did not recognize APP or soluble Aβ. In the following phase II clinical trial, 20% of the vaccine recipients generated anti-Aβ antibody titers. Unfortunately, this trial had to be terminated since 6% of the patients developed meningoencephalitis as a vaccine-related side effect. This side effect was caused by a cellular inflammatory reaction, attributed to a T helper cell type 1 response to epitopes located in the central and C-terminal part of Aβ(1–42) [11], [12].
Multiple ongoing studies aim at improving the Aβ vaccination strategy [13][18]. The use of T helper cell type 2 directing adjuvants [19], [20] or the use of formulations without any adjuvant [21] are under investigation. In addition, it has been proposed to use C-terminally truncated Aβ peptides [22], [23] or peptide mimics (affitopes) of the N-terminus [24]. Antibodies induced by Aβ(1–42) are dominantly directed against the linear N-terminal epitope [25], [26], although generation of conformation-specific antibodies against other regions within aggregated Aβ has been reported [27]. A disadvantage of a vaccine against the N-terminus of Aβ is that it will interfere with the normal physiological processing of APP. It may not be without risk to administer such a vaccine before onset of symptoms of AD.
By targeting an immune response exclusively on misfolded Aβ the undesired response against the N-terminus of Aβ may be avoided all together. A structural model of fibrillar Aβ(1–42) predicts folding of monomeric Aβ(1–42) into a cross-β unit. Two antiparallel extended β-strands, residues 11–25 and 28–42, are connected via a sharp bend around amino acid residues S26 and N27 [28]. Fig. 1 shows a simplification of the original model. A recent study of a particular oligomer of N-Met-Aβ(1–42) suggests a bend around the sequence V24-G-S-N27 [29].
Figure 1
Figure 1
Early folding of human amyloid β (Aβ), around S26 and N27.
The models of folded Aβ show some resemblance with the β-turn structure in surface loops of meningococcal outer membrane protein PorA. Previously, we have stabilized the β-turn conformation of small meningococcal peptides by adding an artificial sequence YNGK′, in which K′ is a modified lysine residue for selective conjugation to a carrier protein, followed by main chain (“head to tail”) amide cyclization [30], [31]. Likewise, it appeared possible to prepare small cyclic peptides mimicking the turn in folded Aβ. A panel of cyclic decameric and undecameric peptides spanning six or seven residues from the region 21–31 of Aβ and YNGK′ was prepared and conjugated to tetanus toxoid (TTd). The conjugates were used for immunization of mice. A tetanus toxoid-conjugate of one of the peptides, cyclo[Aβ(22–28)-YNGK′], elicited antibodies that specifically recognized misfolded Aβ.
Antigen preparation
Oligomeric (≈35 kD) and fibrillar Aβ(1–42) were prepared according to published procedures [32]. A well-established method [33] was used for synthesis of a panel of cyclic decameric and undecameric peptides spanning six or seven residues from the region 21–31 (AEDVG25SNKGA30I) of Aβ (i.e. 23–28, 24–29, 25–30, 21–27, 22–28, 23–29, 24–30, and 25–31) and the artificial stabilizing sequence YNGK′. Linear Ac-K′-Aβ(21–31)-NH2 was prepared to serve as control. The peptides obtained were conjugated to tetanus toxoid (TTd) to give experimental vaccines or to bovine serum albumin (BSA) to give coating antigens for enzyme-linked immunosorbent assay (ELISA ) [34].
Immunization of mice
Balb/c mice were immunized twice with oligomeric or fibrillar Aβ(1–42) without adjuvant or with the different amyloid peptide/TTd-conjugates using aluminum phosphate as adjuvant. The pooled sera from each group immunized with peptide conjugate were analyzed by ELISA using plain TTd, homologous peptide/BSA-conjugate and oligomeric or fibrillar Aβ(1–42) as coating antigens. The sera showed a good antibody titer against TTd and the homologous cyclopeptide (titers of 104–105 were obtained, data not shown).
Six out of eight pooled anti-cyclo-Aβ peptide antisera were not cross-reactive with oligomeric or fibrillar Aβ(1–42) in ELISA or a dot blot assay. Antibodies against cyclo[Aβ(23–29)-YNGK′] showed a weak cross-reactivity. However, anti-cyclo[Aβ(22–28)-YNGK′] antibodies were strongly cross-reactive with oligomeric or fibrillar Aβ(1–42) in ELISA (Fig. 2) and the antibodies recognized Aβ deposits in AD mouse and human brain tissue (Fig. 3). The anti-peptide antibodies did not recognize full length APP in Western blot assay (Fig. 4).
Figure 2
Figure 2
Binding of anti-cyclopeptide antibodies to oligomeric amyloid β (Aβ) as determined by ELISA.
Figure 3
Figure 3
Immunohistochemical staining of brain tissue.
Figure 4
Figure 4
Western blot of a lysate of SW13 adrenal cells transfected with amyloid precursor protein (APP).
The cyclization of the peptide was essential to produce a functional antigen. Conjugates of linear control peptides, i.e. Ac-K′-Aβ(21–31)- NH2 or the fully homologous Ac-K′-Aβ(22–28)-YNG-NH2, induced good anti-peptide antibody titers but the antibodies failed to recognize oligomeric or fibrillar Aβ(1–42) (Fig. 2). The incorporation of the artificial sequence YNGK′ in the cyclopeptide was essential to mimic the turn in folded Aβ(1–42). Incorporation of the sequence GAIK′, i.e. Aβ(29–31)-K′, instead of YNGK′ did not provide a turn-mimicking peptide, since antibodies against cyclo[Aβ(22–31)-K′] were not functional.
The anti-cyclo[Aβ(22–28)-YNGK′] antibodies were very specific for the common Aβ sequence. Amyloid β with the Dutch, Arctic, or Italian mutations (E22Q, E22G, or E22K, respectively) was not recognized. Unrelated but partially homologous proteins like the islet amyloid polypeptide (amylin)or the human Wiskott-Aldrich Syndrome protein (WASP) were also not recognized (data not shown).
Finally, antibodies elicited with oligomeric or fibrillar Aβ(1–42) were non-reactive with cyclo[Aβ(22–28)-YNGK′]-BSA. This was expected since antibodies induced by Aβ(1–42) are directed against the N-terminus [25], [26].
The cross-reactivity of anti-cyclo[Aβ(22–28)-YNGK′] antibodies with oligomeric Aβ(1–42) was confirmed after a second immunization experiment. Individual sera of mice immunized with cyclo[Aβ(22–28)-YNGK′]-TTd were analyzed this time. All sera (8/8) gave a good response against TTd and the homologous peptide (titers 104–105, data not shown), but not all individual sera were clearly cross-reactive with oligomeric or fibrillar Aβ(1–42). Five sera showed titers ≥2000 (Fig. 5), whereas one serum showed no response (titer<100). Two immunizations with oligomeric Aβ(1–42) gave two sera with titers as high as 40×103 and 50×103 on the homologous coating. Three titers were considered to be intermediate (2000–8000) and three titers were low (100–2000).
Figure 5
Figure 5
IgG response of individual Balb/c mice against Aβ (1–42) as determined by ELISA.
Two immunizations with fibrillar Aβ(1–42) gave only two sera with titers 2000 on the homologous coating, two very low responders and four non-responders (titer<100). Poor responsiveness to aggregated Aβ(1–42) was found earlier in clinical and animal studies [35], [36].
In conclusion, cyclo[Aβ(22–28)-YNGK′] mimics a conformational epitope in folded Aβ(1–42) that normally does not induce an antibody response. Cyclo[Aβ(22–28)-YNGK′]-conjugate may be an interesting vaccine candidate against AD. Since the response is directed specifically to misfolded Aβ, it is unlikely that vaccination will interfere with normal physiological processing of the amyloid precursor protein. Thus, vaccination might be possible at an early stage of AD symptoms or before. This seems to be indicated since plaque deposits have already reached a near maximum level at a mild stage of AD [37].
Further studies will aim at improvement of the immune response to cyclo[Aβ(22–28)-YNGK′]-TTd by variation of the dose of cyclopeptide-conjugate, the adjuvant, and the number of administrations, preferably in transgenic AD model mice.
Ethics statement
Tissue from AD patients was obtained from the Netherlands Brain Bank (NBB; Amsterdam, The Netherlands). The NBB performs brain autopsies with short post-mortem intervals, and the brain donors have given written informed consent for using the tissue and for accessing the extensive neuropathological and clinical information for scientific research, in compliance with ethical and legal guidelines [38]. The study was approved by the independent Review Board (“Medisch Ethische Toetsingscommissie, METc”) of the VU University Medical Center, Amsterdam, The Netherlands.
Morphological studies of mouse brain tissue were approved by the Ethical Committee on Animal Experiments of the Royal Netherlands Academy of Arts and Sciences (approval ID: NIN 06.51).
Immunization of mice was approved by the Ethical Committee on Animal Experiments of the National Institute of Public Health and the Environment (approval ID: 2007 00331 and 2008 00179), as required under Dutch Law on the use of laboratory animals. All efforts were made to minimize suffering of the animals.
Materials
Human Aβ(1–42) (Fig. 1), hAβ(1–40/42) analogues, and hIAPP were purchased from AnaSpec (Freemont, CA, USA). AlPO4 suspension (1.5 mg/ml), pH 7.0, and tetanus toxoid (TTd) were produced by the RIVM. Monoclonal antibody 6E10 against Aβ(1–17), was purchased from Abcam (Cambridge, MA, USA) or Covance Research Products, Dedham, MA, USA).
Disaggregation of Aβ(1–42)
Lyophilized Aβ(1–42) was dissolved in trifluoroacetic acid at a concentration of 1.0 mM, left to stand at room temperature for 1 h and dried under a stream of nitrogen and, thereafter, in a vacuum (1 mm Hg) for 15 min. The peptide was then redissolved in hexafluoroisopropanol at a concentration of 1.0 mM and, after 1 h of incubation at room temperature, dried as described above [39]. The peptide was stored at −20°C for 18–20 h.
Preparation of oligomeric or fibrillar Aβ(1–42)
Disaggregated of Aβ(1–42) was dissolved in dimethyl sulfoxide at a concentration of 5.0 mM, diluted 50-fold with either phosphate buffered saline (PBS), pH 7.2, or 10 mM hydrochloric acid. The solution in PBS was incubated at 4°C for 24 h (to give oligomers), whereas the solution in 10 mM HCl was incubated at 37°C for 24 h (to give fibrils) [32].
Peptide synthesis, purification, and conjugation
The α-(2,4-dimethoxybenzyl) ester of Nα-fluorenylmethoxycarbonyl-L-aspartic acid (Fmoc-Asp-ODmb) was coupled through its side-chain to a polymer for the synthesis of peptide amides (for later conversion of the starting Asp into Asn). Synthesis of cyclic peptides, like cyclo[GK′EDVGSNKYN][equivalent]cyclo[EDVGSNKYNGK′] in which K′ is N ε-(S-acetylmercaptoacetyl)lysyl, was then performed as described earlier [33]. The following Aβ-derived and YNGK′-extended cyclopeptides were prepared: 23–28, 24–29, 25–30, 21–27, 22–28, 23–29, 24–30, and 25–31. Linear Ac-K′-Aβ(22–31)-NH2 and linear Ac-K′-Aβ(22–28)-YNG-NH2 were also prepared. The peptides were purified by reverse-phase high performance liquid chromatography and coupled to either bromoacetylated tetanus toxoid or maleimidyl-modified bovine serum albumin (BSA) (modifying reagent: NHS-PEO2-Maleimide, Pierce) [34].
Immunization of mice
Groups of eight female Balb/c mice of 6–8 weeks of age were immunized with 25 µg oligomeric or fibrillar Aβ(1–42) in 0.3 ml phosphate buffered saline (PBS), pH 7.2, without adjuvant or with 50 µg of peptide/TTd-conjugate and 75 µg of AlPO4 in 0.3 ml PBS on days 0 and 28. The mice were bled on day 42 under oxygen/nitrous oxide/isoflurane anesthesia.
Western blot
Human carcinoma SW13 cells [40] were transfected with APP695wt (wild type) and APP695swe (Swedish mutation) and proteins were isolated by homogenization in 0.1 M NaCl, 0.01 M Tris HCl, 0.001 M EDTA, pH 7.6, with proteinase inhibitors. The samples were supplemented with 2× loading buffer (100 mM Tris pH 6.8, 4% SDS, 20% glycerol, 0.2 M DTT, 0.006% bromophenol blue) and run on a 7.5% SDS-PAGE gel. The gel was semi-dry blotted on nitrocellulose and probed overnight with the 6E10 antibody (1[ratio]1000) or the mouse anti-cyclo[Aβ(22–28)-YNGK′] serum (1[ratio]500). After washing, the blots were incubated with anti-mouse Cy5 (1[ratio]300), bands were visualized with the Odyssey Infrared Imaging System.
Dot blot
Dilutions of cell lysates (WASPpos HL60 cells and WASPneg Vero cells) in PBS were spotted (1 µl/spot) on polyvinylidene difluoride membrane (Immobilon-P, pore size 0.45 µM, Millipore). The blots were incubated with mouse anti-cyclo[Aβ(22–28)-YNGK′] serum, control monoclonal antibody 6E10, or polyclonal anti-WASP antibodies. After washing, the blots were incubated with horseradish peroxidase-conjugated 2nd antibody, and visualized with GZ11 signal reagent [41].
ELISA
Microtiter plates (Greiner 655092) were coated with Aβ(1–42) or peptide-BSA conjugates. Freshly prepared Aβ(1–42) oligomers or fibrils were diluted to a final concentration of 2.5 µM (11.3 µg/ml) in 0.04 M sodium carbonate/bicarbonate buffer, pH 9.7. Peptide-BSA conjugates in phosphate buffered saline, pH 7.2 (PBS), had a total protein concentration of 0.5 µg/ml. Aliquots (100 µl) of these solutions were transferred into wells of the plates. The plates were incubated for 90 min at 37°C. The plates were further processed as described earlier [42]. Titers were calculated as the reciprocal serum dilution at 50% of the maximum optical density (OD50).
Immunohistochemical staining
Human brain sections of the hippocampus of several donors with Alzheimer disease, Braak 5 or 6 [43], were used (Netherlands Brain Bank). In addition, brain sections of 9 month old APPswe/PS1dE9 [42] mice with a significant plaque deposition were used. Cryosections (10 µm) were cut from unfixed, directly frozen tissue, thaw-mounted, dried for 1 hour and stored in a sealed box at −20 C. For immunostaining, sections were fixed in 4% PFA-PBS solution for 10 min, washed in 0.05 M phosphate buffer (PB) for 10 min with 2 exchanges and blocked with 10% normal donkey serum (NDS) +0.4% Triton X-100 in 0.05 M PB for 1 hour at RT. The blocking solution was discarded and diluted mouse sera (1[ratio]300; first antibody) in 3% NDS +0.4% Triton X-100 in 0.05 M PB was added and incubated O/N at RT. Sections were washed with 0.05 M PB; at least 30 min with one or more exchanges. Then sections were incubated with Donkey-anti-Mouse ~Cy3 1[ratio]1400 in 0.05 M PB for 2 hours. Sections were washed with 0.05 M PB; at least 30 min with one or more exchanges. Sections were sealed in Vectashield with Dapi (Vector). Mouse Monoclonal 6E10 to beta amyloid 3–8 (Signet-Covance) was used as positive control (1[ratio]15,000).
Acknowledgments
The human brain tissue was obtained from The Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam.
Footnotes
Competing Interests: The authors have read the journal's policy and have the following conflicts. PH and GPJMvdD have filed a patent application entitled “Vaccine against amyloid folding intermediate.” EP08159385.7 (2008), WO2010002251 (A1) (2010). The RIVM is a Government Institute. The application was filed on behalf of “the Kingdom of The Netherlands.” It does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials.
Funding: The authors have no support or funding to report.
1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387–403. [PubMed]
2. Goedert M, Spillantini MG. A century of Alzheimer's disease 1. Science. 2006;314:777–781. [PubMed]
3. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008;283:29639–29643. [PubMed]
4. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101–112. [PubMed]
5. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci. 2010;30:10369–10379. [PubMed]
6. Klein WL, Stine WB, Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging. 2004;25:569–580. [PubMed]
7. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23–35. [PubMed]
8. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172–1184. [PubMed]
9. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177. [PubMed]
10. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8:1270–1275. [PubMed]
11. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–1562. [PubMed]
12. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008;5:194–196. [PubMed]
13. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders 2. Annu Rev Neurosci. 2008;31:175–193. [PMC free article] [PubMed]
14. Foster JK, Verdile G, Bates KA, Martins RN. Immunization in Alzheimer's disease: naive hope or realistic clinical potential? 1. Mol Psychiatry. 2009;14:239–251. [PubMed]
15. Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother. 2007;7:1535–1548. [PubMed]
16. Solomon B. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease. Rejuvenation Res. 2008;11:349–357. [PubMed]
17. Wisniewski T. AD vaccines: conclusions and future directions 3. CNS Neurol Disord Drug Targets. 2009;8:160–166. [PubMed]
18. Woodhouse A, Dickson TC, Vickers JC. Vaccination strategies for Alzheimer's disease: A new hope? Drugs Aging. 2007;24:107–119. [PubMed]
19. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505–514. [PMC free article] [PubMed]
20. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine. 2006;24:2275–2282. [PMC free article] [PubMed]
21. Cao C, Lin X, Wahi MM, Jackson EA, Potter H., Jr Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. BMC Neurosci. 2008;9:25. [PMC free article] [PubMed]
22. Lemere CA. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine 2. Prog Brain Res. 2009;175:83–93. [PMC free article] [PubMed]
23. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108–119. [PMC free article] [PubMed]
24. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, et al. Development of Affitope Vaccines for Alzheimer's Disease (AD) - From Concept to Clinical Testing 1. J Nutr Health Aging. 2009;13:264–267. [PubMed]
25. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol. 2005;58:430–435. [PubMed]
26. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283–297. [PubMed]
27. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, et al. Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis. 2010;39:301–310. [PMC free article] [PubMed]
28. Olofsson A, Sauer-Eriksson AE, Ohman A. The solvent protection of alzheimer amyloid-beta-(1–42) fibrils as determined by solution NMR spectroscopy. J Biol Chem. 2006;281:477–483. [PubMed]
29. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry. 2009;48:1870–1877. [PubMed]
30. Oomen CJ, Hoogerhout P, Bonvin AM, Kuipers B, Brugghe H, et al. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J Mol Biol. 2003;328:1083–1089. [PubMed]
31. Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van AL, et al. Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol. 2005;351:1070–1080. [PubMed]
32. Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612–11622. [PubMed]
33. Brugghe HF, Timmermans HA, Van Unen LM, Ten Hove GJ, Van de Werken G, et al. Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein. Int J Pept Protein Res. 1994;43:166–172. [PubMed]
34. Drijfhout JW, Hoogerhout P. Methods of preparing peptide-carrier conjugates. In: Chan WC, White PD, editors. Fmoc Solid Phase Peptide Synthesis: A Practical Approach: Oxford University Press; 2000. pp. 229–241.
35. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial 1. Lancet. 2008;372:216–223. [PubMed]
36. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77–84. [PubMed]
37. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461:916–922. [PMC free article] [PubMed]
38. Huitinga I, Rademaker M, Klioueva N. The art of brain banking in Europe: ethical, legal and practical guidelines for donor recruitment, tissue handling and tissue distribution. J Neural Transm. 2008;115:1715.
39. Zeng H, Zhang Y, Peng L, Shao H, Menon NK, et al. Nicotine and amyloid formation. Biol Psychiatry. 2001;49:248–257. [PubMed]
40. Sarria AJ, Lieber JG, Nordeen SK, Evans RM. The presence or absence of a vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. J Cell Sci. 1994;107(Pt 6):1593–1607. [PubMed]
41. Zomer G, Hamzink M, de Haan A, Kersten G, Reubsaet K. Development and optimization of a quantitative Western blot and dot blot procedure for the determination of residual host cell proteins present in inactivated polio vaccine using GZ11 based signal reagent. In: Shen X, Yang XL, Zhang XR, Cui ZJ, Kricka LJ, editors. Bioluminescence and Chemiluminescence Light Emission: Biology and Scientific Applications: World Scientific; 2009. pp. 287–290.
42. Westdijk J, Van den IJssel J, Thalen M, Beuvery C, Jiskoot W. Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. J Immunoassay. 1997;18:267–284. [PubMed]
43. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. [PubMed]
Articles from PLoS ONE are provided here courtesy of
Public Library of Science